This hypothesis is partially confirmed by the low antigenic specificity; indeed, only 9/19 ANA ≥ 1:160 positive MDS patients had a positive result in the immunoenzymatic assays commonly used for the evaluation of the main ANA targeted antigens. Here, BTG3 is linked to myelodysplastic syndrome.